Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2

Gut microbiota dysbiosis contributes to the development of hypertension

(2017) Jing Li et al.   Microbiome

Pathogenesis of Mycoplasma pneumoniae: An update

(2016) R Chaudhry et al.   Indian Journal of Medical Microbiology

Mycoplasmal lipoprotein p37 binds human protein HER2

(2016) Jun Wu et al.   MICROBIOLOGICAL RESEARCH

Efficacy of Antimicrobial Therapy forMycoplasma genitaliumInfections

(2015) Lisa E. Manhart et al.   CLINICAL INFECTIOUS DISEASES

Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism

(2015) Helena Joyce et al.   Expert Opinion on Drug Metabolism & Toxicology

The gut microbiota in human energy homeostasis and obesity

(2015) Michael Rosenbaum et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma

(2015) Chang-Yu Chen et al.   Oncotarget

Mycoplasma hyorhinis -encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs

(2015) Johan Vande Voorde et al.   FEBS Open Bio

Detection of mycoplasma infection in circulating tumor cells in patients with hepatocellular carcinoma

(2014) Hong Seo Choi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo

(2014) Kamlesh Sodani et al.   BIOCHEMICAL PHARMACOLOGY

Mycoplasma hyorhinis induces epithelial-mesenchymal transition in gastric cancer cell MGC803 via TLR4-NF-κB signaling

(2014) Hongying Duan et al.   CANCER LETTERS

Mycoplasma Hyorhinis Infection Promotes NF- B-Dependent Migration of Gastric Cancer Cells

(2014) H. Duan et al.   CANCER RESEARCH

Annexin A2: Its Molecular Regulation and Cellular Expression in Cancer Development

(2014) Chi-Yun Wang et al.   DISEASE MARKERS

Nucleoside-catabolizing Enzymes in Mycoplasma-infected Tumor Cell Cultures Compromise the Cytostatic Activity of the Anticancer Drug Gemcitabine

(2014) Johan Vande Voorde et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Pyrimidine Nucleoside Phosphorylase ofMycoplasma hyorhinisand How It May Affect Nucleoside-Based Therapy

(2014) J. Vande Voorde et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment

(2013) Aleksandar D. Kostic et al.   Cell Host & Microbe

Mycoplasma genitalium

(2013) Lisa E. Manhart   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Cancer cell killing via ROS: To increase or decrease, that is the question

(2010) Jie Wang et al.   CANCER BIOLOGY & THERAPY

ABC Efflux Pump-Based Resistance to Chemotherapy Drugs

(2009) Paul D. W. Eckford et al.   CHEMICAL REVIEWS

Structural Insights into the Extracytoplasmic Thiamine-Binding Lipoprotein p37 of Mycoplasma hyorhinis

(2009) K. H. Sippel et al.   JOURNAL OF BACTERIOLOGY

Improvement of purine and pyrimidine antimetabolite-based anticancer treatment by selective suppression of mycoplasma-encoded catabolic enzymes

(2009) Sandra Liekens et al.   LANCET ONCOLOGY

The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: Implications for cancer therapy

(2008) Annelies Bronckaers et al.   BIOCHEMICAL PHARMACOLOGY

p37 from Mycoplasma hyorhinis promotes cancer cell invasiveness and metastasis through activation of MMP-2 and followed by phosphorylation of EGFR

(2008) M. Gong et al.   MOLECULAR CANCER THERAPEUTICS

Innate immunity and intestinal microbiota in the development of Type 1 diabetes

(2008) Li Wen et al.   NATURE